Target- |
Mechanism- |
|
|
|
Inactive Indication- |
Drug Highest PhaseApproved |
First Approval Ctry. / Loc.CN |
First Approval Date01 Jan 1997 |
穿龙骨刺胶囊治疗骨质增生骨刺疼痛的随机双盲多中心平行对照临床试验
[Translation] A randomized, double-blind, multicenter, parallel controlled clinical trial of Chuanlong Guci Capsule in the treatment of bone spur pain caused by bone hyperplasia
初步评价穿龙骨刺胶囊治疗骨刺疼痛的有效性和安全性。
[Translation] To preliminarily evaluate the efficacy and safety of Chuanlong Guci Capsule in the treatment of bone spur pain.
100 Clinical Results associated with Taiji Group Chongqing Tongjunge Pharmaceutical Plant Ltd.
0 Patents (Medical) associated with Taiji Group Chongqing Tongjunge Pharmaceutical Plant Ltd.
100 Deals associated with Taiji Group Chongqing Tongjunge Pharmaceutical Plant Ltd.
100 Translational Medicine associated with Taiji Group Chongqing Tongjunge Pharmaceutical Plant Ltd.